Amphastar Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
AMPH$29.06-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| · · · · · · · · · · · · · · · · · · · · · · · | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · · · · · · · Accumulated · · Treasury Stock · · · | |||||||||||||||||
| · · · · · · · Additional · · · · · Other · · · · · · · · | |||||||||||||||||
| · · · · · · · Paid-in · · Retained · · Comprehensive · · · · · · · · | |||||||||||||||||
| · · Shares · · Amount · · Capital · · Earnings · · loss · · Shares · · Amount · · Total | |||||||||||||||||
| Balance as of December 31, 2022 | 58,110,231 | | $6 | | $455,077 | | $271,723 | | $(8,624) | (9,998,162) | | $(189,524) | | $528,658 | | ||
| Net income | — | | — | | — | | 137,545 | | — | — | | — | | 137,545 | | ||
| Other comprehensive income | — | | — | | — | | — | | 146 | — | | — | | 146 | | ||
| Purchase of treasury stock | — | | — | | — | | — | | — | (1,338,757) | | | (58,144) | | (58,144) | | |
| Issuance of treasury stock in connection with the Company's equity plans | | — | | — | | (237) | | — | | — | 15,606 | | | 237 | | — | |
| Issuance of common stock in connection with the Company's equity plans | 1,279,963 | | — | | 10,974 | | — | | — | — | | — | | 10,974 | | ||
| Share-based compensation expense | — | | — | | 20,242 | | — | | — | — | | — | | 20,242 | | ||
| Balance as of December 31, 2023 | 59,390,194 | | $6 | | $486,056 | | $409,268 | | $(8,478) | (11,321,313) | | $(247,431) | | $639,421 | | ||
| Net income | — | | — | | — | | 159,519 | | — | — | | — | | 159,519 | | ||
| Other comprehensive loss | — | | — | | — | | — | | (703) | — | | — | | (703) | | ||
| Purchase of treasury stock | — | | — | | — | | — | | — | (1,919,670) | | | (85,458) | | (85,458) | | |
| Issuance of treasury stock in connection with the Company's equity plans | | — | | — | | (175) | | — | | — | 11,550 | | | 175 | | — | |
| Issuance of common stock in connection with the Company's equity plans | 1,456,930 | | — | | (4,849) | | — | | — | — | | — | | (4,849) | | ||
| Share-based compensation expense | — | | — | | 24,368 | | — | | — | — | | — | | 24,368 | | ||
| Balance as of December 31, 2024 | 60,847,124 | | $6 | | $505,400 | | $568,787 | | $(9,181) | (13,229,433) | | $(332,714) | | $732,298 | | ||
| Net income | — | | — | | — | | 98,094 | | — | — | | — | | 98,094 | | ||
| Other comprehensive income | — | | — | | — | | — | | 3,867 | — | | — | | 3,867 | | ||
| Purchase of treasury stock | — | | — | | — | | — | | — | (2,915,580) | | | (75,586) | | (75,586) | | |
| Issuance of treasury stock in connection with the Company's equity plans | | — | | — | | (152) | | — | | — | 10,627 | | | 152 | | — | |
| Issuance of common stock in connection with the Company's equity plans | 932,759 | | — | | 2,855 | | — | | — | — | | — | | 2,855 | | ||
| Share-based compensation expense | — | | — | | 27,277 | | — | | — | — | | — | | 27,277 | | ||
| Balance as of December 31, 2025 | 61,779,883 | | $6 | | $535,380 | | $666,881 | | $(5,314) | (16,134,386) | | $(408,148) | | $788,805 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.